Anúncio
Anúncio

MYGN

MYGN logo

Myriad Genetics Inc

6.57
USD
Patrocinado
-0.06
-0.87%
08 de jan., 16:00 UTC -5
Encerrado
exchange

Pós-Mercado

6.57

-0.01
-0.11%

Relatórios de Lucros MYGN

Rácio de surpresa positiva

MYGN separação 17 de 20 últimas estimativas.

85%

Próximo Relatório

Próxima semana
Data do Próximo Relatório
15 de jan. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$211.44M
/
-$0.01
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+2.79%
/
--
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+0.40%
/
-133.33%

Myriad Genetics Inc earnings per share and revenue

On 03 de nov. de 2025, MYGN reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of 0.00 USD, resulting in a 100.00% surprise. Revenue reached 205.70 milhão, compared to an expected 208.99 milhão, with a -1.58% difference. The market reacted with a -21.03% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of -0.01 USD, with revenue projected to reach 211.44 milhão USD, implying an -- of --% EPS, and aumentar of 2.79% in Revenue from the last quarter.
FAQ
For Q3 2025, Myriad Genetics Inc reported EPS of $0.00, beating estimates by 100%, and revenue of $205.70M, -1.58% below expectations.
The stock price moved down -21.03%, changed from $8.18 before the earnings release to $6.46 the day after.
The next earning report is scheduled for 15 de jan. de 2026.
Based on 15 analistas, Myriad Genetics Inc is expected to report EPS of -$0.01 and revenue of $211.44M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio